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ABSTRACT
We have used the gel retardation and DNAase I assays to investigate the
binding of nuclear proteins to the human B-globin promoter. Upon incubation
with 3-globin promoter fragments containing the duplicated CACCC boxes,
nuclear proteins from human erythroid cells generate complexes yielding four
retarded bands in acrylamide gels; the three slowest bands are common to
both erythroid and non erythroid cells. The fast band is present only in
K562 erythroleukemic cells induced to differentiation and hemogloblin
accumulation and in fetal and adult erythroblasts, but absent in uninduced
K562 cells. Binding occurs on a short DNA region including the proximal CACCC
box, and is not significantly competed by excess y-globin fragments
containing the CACCC box; the CACCC box appears to be essential for this
binding, as shown by the failure of a fragment containing a natural B-
thalassemic mutation (-87, C 'G) to bind significantly to nuclear factors.
These data suggest that the erythroid specific CACCC binding factor might
play a role in the developmental activation of B-globin transcription.
INTRODUCTION
The human B- and y-globin genes are differentially expressed during
development; the B-globin gene is transcribed at a low level (5-10% relative
to total non C-globin RNA) already during fetal life (starting at the 5
week) and at the maximal level after birth, while the 7-globin genes are
expressed almost exclusively during the embryonic and fetal periods. This
transcriptional selectivity has been reproduced, in part, using cloned genes
(or their fragments) transfected into cultured erythroid cells or inserted
into the germ line of transgenic mice (1-21).
In addition, in vitro mutagenesis of the (murine) B-globin promoter has
precisely defined sequences (TATA, CCAAT and CACCC boxes) controlling
transcription in non-erythroid cells (in the presence of an enhancer) as well
as in erythroid cells (5,22). Some of these sequences correlate with those
defined on the basis of the existence of natural B-globin mutations
(thalassemias), severely affecting B-globin gene transcription (23-25).
In spite of this large body of information, little is known of the sequences
determining erythroid- and developmentally-specific regulation, and of their
interaction with controlling factors acting in trans. This in part stems from
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the difficulties involved in transfecting with cloned genes tne proper cells,
human erythroblasts.
As an alternative approach to defining potentially important regulatory
sequences, we have examined the in vitro binding to the B-globin promoter of
nuclear proteins from a variety of erythroid and non-erythroid human cells.
Here we show that an erythroid specific factor binds to the normal, but not
to a mutated, B-globin CACCC box; this factor is absent in erythroid cells
(K562) not producing B-globin, but can be induced by agents causing the
differentiation of these cells, and is additionally present in human fetal
and adult erythroblasts properly synthesizing B-globin.
MATERIAL AND METHODS
Cells
Human cell lines used were the following: K562 (erythroleukemia cells
synthesizing embryonic and fetal hemoglobins), Molt 4 (T-lymphoma cells),
U937 and THP-1 (promonocytic leukemia), Raji (EBV-positive B-lymphoma cells)
and HeLa (uterine carcinoma cells). K562 were induced to differeliciation oy
addition of 60 PM bovine hemin for various times; U937 and THP-1 cells were
induced to differentiation to macrophages by addition of 12-0-
Tetradecanoylphorbol-13-acetate (TPA) at a concentration of 50 ng/ml.
Fetal liver erythroblasts (approx4mately 95% pure) were obtained (26) from
livers of fetuses (at the 16-18 week of gestation) legally aborted for
social or medical reasons. Informed consent was obtained from mothers.
Adult marrow erythroblast were obtained from the bone marrow (BM) of patients
with autoimmune haemolytic anaemia, whose smear revealed that more than 50-
60% mononuclear cells were erythroblasts at different stages of
differentiation. The BM aspirate was layered onto a 1077 Ficoll-Hypaque
gradient. Cells at the interfacies were recovered, washed three times with
sterile phosphate buffered saline (PBS) and incubated with HLe 1 monoclonal
antibody (MoAb, Becton Dickinson, Mountain View, California, cat. N. 7460)
which detects the CD45 antigen expressed on the surface of most
lymphohaemopoietic cells with the notable exception of erythroid precursors.
BM mononuclear cells resuspended in sterile PBS at the concentration of 30 x
10 cells/ml were incubated with HLe 1 purified ascitic protein (1 mg/ml at
1:1000 final dilution following dialysis and filtration) for 45'. at room
temperature. After three further washings with PBS-BSA (Bovine Serum Albumin)
1%, the CD45+ cells were revealed by means of magnetic beads coated with Goat
anti-mouse Ig (Dynabeads M-450, Dynal, Oslo, cat. N. 11006) and removed with
the related magnetic particle concentrator (Dynal, Oslo, cat. N. 12002). The
proportion of erythroblasts in the CD45-fraction was assessed morphologically
on cytospins and proved to be 90%.
DNA fragments
A HinfI-NcoI fragment of the B-globin promoter (from -280 to +49) was
subcloned into the pGEM plasmid, with Hind III linkers; smaller fragments
3wre generated by digestion with the indicated enzymes, and 5'-labelled with
P-ATP and T-4 Polynucleotide Kinase.
Nuclear extracts
Nuclear extracts were prepared exactly according to ref. 27.
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Electrophoretic mobility assay
The labelled fragments (0.1-0.5 ng), were incubated (28) with nuclear
extracts (5 jg of protein unless otherwise indicated) from various cell
types, in the presence of optimal amounts (6 jig in a 20 1l reaction) of poly
(dI-dC), electrophoresed in 50 mM Tris borate pH8.2 and autoradiographed
(28).
DNAse I foot-printing 32
DNA fragments were 5' end labelled with polynucleotide kinase and P-ATP and
secondarily cut with the appropriate restriction enzyme to leave a single
labelled 5' end. Fragments were incubated with nuclear extracts for 30' at
25°C; DNAse I (2 ltg/ml of reaction mixture) was added, and the samples
incubated for 2' at 20°C; reactions were stopped with 5mM EDTA, the
incubation mixture was electrophoresed, tha bands located by autoradiography,
the fragments eluted from the excised bands, phenol extracted, ethanol
precipitated and analyzed on sequencing gels.
DMS interference (29)
A RsaI-BstNI fragment, 5'-end labelled at the BstNI site, was partially
methylated with DMS (200C, 11', 1 ltl DMS/20 Ml reaction); after stopping the
reaction with 200 mM Tris Acetate, 0.2 M B-mercaptoethanol, 0.2 mM EDTA, the
fragment was ethanol precipitated, incubated with nuclear extracts and
migrated on polyacrylamide gels. Bands were recovered, piperidine treated
(900C, 30', 1 M piperidine), extensively lyophilized and analyzed on
sequencing gels.
RESULTS
Tissue specific and ubiquitous nuclear factors binding to the 1B-globin
promoter.
To investigate the binding of nuclear proteins to the B-globin promoter, the
gel shift assay (28) was used. Using the full Hind III fragment of fig.1
(data not shown) or smaller fragments derived from it, a number of common
bands are visible with all extracts tested (from erythroid and non-erythroid
cells) (fig.1). However, an additional fast band (number 4, arrow) is clearly
visible with extracts from induced K562 or fetal liver cells, but not from
uninduced K562 or non erythroid cells (Molt 4); a slight, but reproduc-:ble
difference in mobility between band 4 generated with K562 or fetal liver
erythroblasts, respectively, is consistently observed; the reasons for the
difference have not yet been investigated. The location of the protein
binding site responsible for this band can be identified on the basis of the
observation that the band appears with both RsaI-Hind III and DdeI-Hind III
fragments (from -127 and -113 respectively to +49) (fig.la and b) and with
Hind III-BstNI fragment (-280 to -64) (fig.lc), suggesting region -113 to -64
as the relevant site; this is indeed the case (fig.ld). With this fragment,
three common bands (1-3) are visible with all extracts, although their
relative amounts are very variable between different cell types.
Competition experiments indicate that the tissue specific protein binds much
more efficiently to the B-than to the'Y-globin promoter.
To demonstrate the specificity of binding to the B-globin promoter,
progressively increasing amounts of unlabelled Hind III-BstNI fragment were
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Figure 1.
DNA-protein complexes formed in vitro with the f3-globin promoter.
a: RsaI-Hind III fragment. Lanes: 1: no extract; 2: uninduced K562, 3:
hemin-induced K562; 4: purified liver erythroblasts; 5: Molt 4.
b: DdeI-Hind III fragment. Lanes: 1: uninduced K562; 2: hemin-induced K562;
3: purified fetal liver erythroblasts; 4: Molt 4.
c: Hind III-BstNI fragment. Lanes: 1: uninduced K562; 2: hemin-induced K562;
3: purified fetal liver erythroblasts; 4: Molt 4.
d: DdeI-BstNI fragment. Lanes: 1: hemin-induced K562; 2 uninduced K562; 3:
Molt 4; 4: purified fetal liver erythroblasts.
Asterisk indicates a complex that is formed with uninduced K562 extracts and
is absent in fetal liver erythroblasts. It has been located on an upstream
fragment and will be described in detail elsewhere.
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added to the same labelled fragment in the presence of induced K562 cells
extract (fig.2); all four bands are efficiently competed already at a 10-30
fold excess of competitor. On the contrary, a y-globin promoter fragment (-
299 to -53 relative to the CAP site), containing sequences homologous to the
B-globin promoter binding site (CACCC and CCAAT boxes) is unable, at the same
molar excess, to compete significantly band 4; it should be noticed that the
ubiquitous bands 1-3 are already greatly competed at a 10-30 fold excess.
Footprint and DMS interference experiments show protection of the proximal
CACCC box of the B-globin promoter.
The DdeI-BstNI fragment contains both the CACCC and CCAAT boxes, which are
well known trascription activating elements (22). To investigate whether any
10 30 100 - 10 30 100
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Figure 2.
Competition experiments using hemin induced K562 nuclear extract and labelled
Hind III-BstNI fragment with homologous and non-homologous unlabelled
competitors.
Lanes: 1-3: 10,30,100 fold molar excess of unlabelled B-globin HindIII-BstNI
fragment; 4: no specific competitor; 5-7: 10, 30, 100 fold molar excess
of y-globin promoter fragment containing CACCC and CCAAT boxes (-299 to -53
relative to the CAP site). Bands are labelled 1-4 as in fig. lc, d.
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Figure 3.
DNAseI protection and DMS interference assays.
a: DNAse I protection assay of the DdeI-BstNI fragment incubated with nuclear
extract from purified fetal liver erythroblasts. G+A: chemical degradat'ion
ladder of G and A; F: unbound fragments 4 and 1: retarded bands 4 and 1
respectively of Fig.1d. The positions of the proximal and distal CACCC boxes
are indicatCed by arrows; the footprint by brakets.
b,c: DMS interference analysis of the RsaI-BstNI fragment. b: F: unbound
fragment; B4: bani B4. c: F: unbound fragment; 81: band Bl.
Protected guanines are indicated by open circles.
of these elements is involved in the binding, bands 1 and 4 were footprinted
with DNaseI (30). After DNaseI treatment, the incubation mixture was run on
acrylamide gels, individual bands were recovered, denatured and further
analysed on sequencing gels. With both bands protection was centered on the
proximal CACCC box, extending approximately from nucleotide -95 to nucleotide
-82 (fig.3a). The faint bands 2 and 3 gave essentially the same result (data
not shown). To better define the nucleotides involved in the binding, DMS
interference experiments (29) were performed. A RsaI-BstNI fragment
(extending from -127 to -64), 51 labelled at the BstNI site (non coding
strand), was partially methylated with DMS before the binding reaction. The
bound and free fragments were separated and the purified bands analyzed,
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Figure 4.
Com-petition experimentLs using hemin--induced K562 extracts and 51-labelled
DdeI-BstNI fragment with unlabelled normal and 13-thalassemic (C -C
substitution, position -87) DdeI-BstNI synthetic oligonucleotides.
The relative molar excess of unlabelled competitor DNA is indicated for each
lane. Competitions with a normal DdeI-BstNI fragment and an unrelated
fragment H28 (a synthetic oligonucleotide containing sequences from histone
H2B gene promoter) were included as controls.
after piperidine treatment, on sequencing gels. Fig.3b, c shows that
methylation of the guanines at positions -86, -87, -88, -90, -92 and -93
strongly interferes with the ability of the fragment to bind to nuclear
factors generating bands 1 and 4 (similar results were also obtained with
bands 82 and B3, not shown). Interestingly, the guanines at positions -101,
-102, -103, -105, -107 and -108 corresponding to the distal CACCO box, show
similar intensities of reaction with both the free and the bound fragments,
indicating that these nucleotides are not detectably involved in binding.
ThiLs result is in agreement with the lack of DNAse I protection of the distal
CACCC box shown in fig.3a.
Identical results were obtained with band 4 generated with either induced
K562 cells or fetal liver erythroblasts (not shown).
A naturally occurring mutation in the CACCC box severely affects nuclear
protein bindig
Some inherited defects of 13-globin gene expression are due to single point
mutations in the CACCC box (25); we therefore asked whether any correlation
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Figure 5.
Kinetics of complex 4 induction by hemin in K562 cells (a); binding patterns
in other inducible cell lines (b).
a: lanes: 1: uninduced exponentially growing K562 cells; 2-3: hemin-induced
K562 cells, 2 hours and 24 hours, after hemin addition. Benzidine
positivity was greater than 90% at day 4. 4: 1-B-D-Arabinofuranosylcytosine-
induced K562 cells, 4 days after induction. Asterisk as in Figure 1 c.
b: lanes: 1: purified fetal liver erythroblasts; 2: uninduced U937 cells; 3:
TPA-induced U937 cell; 4: uninduced THP-1 cells; 5: TPA-induced TPH-1 cells.
The fragment used in these experiments was Hind III-BstNI.
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existed between the occurrence of mutation in the CACCC box and defective
binding of any of the factors generating bands 1-4. A synthetic double
stranded oligonucleotide exactly corresponding to the DdeI-BstNI fragment,
but carrying a C -G substitution at position -87, was synthesized; this
oligonucleotide generates extremely weak bands with either erythroid or non
erythroid nuclear extracts (less than 5% relative to the normal fragment)
(data not shown). To provide a better estimate of the relative affinities of
the normal and mutated fragments, we performed competition experiments. While
the normal unlabelled DdeI-BstNI fragment almost completely competes all four
bands at a 25-fold molar excess, the mutated oligonucleotide gives about 50%
competition at a 250-fold molar excess (fig.4). To ascertain that no
aspecific competition occurs at high molar excesses, an unrelated
oligonucleotide of a similar size (a fragment from the Histone H2B gene
containing an "octamer" (32) sequence) was also used, showing no effect.
The protein generating band 4 is rapidly induced in K562 cells following
erythroid differentiation and is not present in other hematopoietic cell
lines.
Fig.5a shows that band 4 is already visible within two hours following
hemin-induction of differentiation in K562 cells, and increases to a high
level within 24 hours. In addition, the appearance of the new band is not
strictly dependent on the nature of the chemical inducer, as the same band is
12 3 4 5
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Figure 6.
DNA-protein complexes formed with adult erythroblasts extract.
Lanes: 1: hemin-induced K562, 3 pgr of protein; 2: fetal liver erythroblasts,
3 ygs of protein; 3 and 4: adult erythroblasts, 0.5 and 1 ugr of protein; 5:
Raji, 3 /Ags of protein. Fragment used was HindIII-BstNI.
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Figure 7.
Proteinase K digestion of uninduced K562 extract.
Lanes: 1: no proteinase K; 2-4: 1, 10, 100 ngr of proteinase K, 10' at 37°C;
5:induced K562, untreated. Arrows show shifted bands resulting froms
digestion. Fragment used was RsaI-BstNI.
present at similar levels (at day four) following treatment with a cytos-tatic
drug (1-B3-D-Arabinofuranosylcitosine, Ara-C) capable of inducing terminal
differentiation and hernoglobin synthesis in K562 cells (33).
In addi-tion to Molt 4 (see fig.l), several non erythroid cell lines were also
examined (EKeLa, the B-cell lymphoma Raji, the monocytic leukemia lines U937
and THP-1). Nione of these lines shows a band similar in mobility to band 4,
even after induction of terminal differentiation with tetradecanoylphorbol
acetate (TPA) (fig.5b).
The protein generating band 4 is present in adult human erythroblasts
actively synthesizing 0-globin.
We have already shown (fig.1) that band 4 is generated using extracts from
fetal liver erythroblasts. Although these cells synthesize 0-globin, the
majority ( 90%) of non-O( globin chains is represented by y-globin. We
therefore purified erythroblasts from the bone marrow of adult patients being
examined for severe non thalassemic anemias, whose non-Coglobin synthesis is
represented almost exclusively by B-globin. Niuclear extracts from these cells
yield a strong band 4, in addition to weaker bands 1-3 (fig. 6); based on the
proportion of nuclear extract used in these binding experiments, we calculate
that the protein responsible for band 4 is approximately two-three- fold more
abundant in adult erythroblasts than in fetal liver or induced K56'' cells.
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Control experiments indicate that B4 is not generated by proteolysis acting
on Bl-B3.
Recent work (29) has shown that treatment of DNA binding proteins with a
variety of proteases can release a protease-resistant DNA binding "core"
domain in an active form; as band B4 is fastest migrating one, it might
represent the product of protease degradation of bands Bl-B3. We therefore
treated extracts from uninduced or induced K562 cells with various amounts of
proteinase K (29); fig.7 (using uninduced K562 cells extract) indicates that
this treatment, though generating fast-migrating DNA-binding proteins, does
not generate any band comparable to band B4. As the specificity of the
exogenous protease used might differ from that of endogenous K562 proteases
(if any were present) we preincubated at 370C K562 extracts (induced and non
induced) under variuos ionic conditions before the binding reactions. These
experiments (data not shown) indicate a remarkable stability of the binding
pattern for at least 30 minutes of preincubation and no generation of band B4
from the slower bands B1-B3. Similarly, mixing experiments between extracts
generating and non-generating band B4, yield a band B4 of intermediate
intensity, ruling out the possibility that the absence of band B4 in certain
extracts results from protease activity. These data indicate that band B4 is
unlikely to represent a protease digestion artefact.
DISCUSSION
Previous studies of the transcriptional regulation of the human B-globin
gene gave contrasting results as to the role of the B-globin promoter. In
transgenic mice, a B-globin promoter containing 614 nucleotides flanking the
CAP site is unable to drive transcription of a hybrid B-globin or B-globin
metallothionein gene (21); in addition, a complete B-globin gene containing
only 48 nucleotides 5' to the CAP site is still transcribed specifically, at
a low level, in erythroid cells (11), suggesting that the B-globin promoter,
per se, might be a relatively unimportant element for erythroid specific
transcription of the B-globin gene. In contrast, in mouse erythroleukemia
cells the B-globin promoter used in the present experiments (18) or a
slightly longer one (20) is able to drive erythroid- and developmentally-
specific expression of the chloramphenicol-acetyl-transferase and neo-
resistance genes, respectively. In these cells, the B-globin promoter can
also be significantly activated following hexamethylenbisacetamide-induced
cell differentiation (7). The latter results suggest that, in addition to
other sequences, possibly represented by the recently described 3' enhancer
(19), B-globin promoter sequences may be involved in the erythroid- and
developmentally-specific regulation of B-globin gene expression. The question
then arises whether promoter sequences (TATA, CCAAT and CACCC boxes)
previously defined as being important in general for transcription (22) are
involved in specific erythroid regulation. We have addressed this problem ky
looking at nuclear proteins capable of interacting in vitro with B-globin
promoter fragments. We show here that a nuclear protein present in erythroid
cells, is able to interact with a short DNA region including the proximal
CACCC box of the B-globin promoter (fig.3). This nuclear protein is specific
for erythroid cells, being observed in differentiating erythroleukemic K562
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cells (but not in uninduced K562 cells), as well as in fresh erythroblasts
purified either from human fetal livers or from adult bone mar2ows.
The binding to the CACCC box region requires the integrity of this element,
as shown'by the strong effect of a C ,.G substitution at position -87; tlhis
mutation is known to greatly decrease 3-globin gene transcription in vivo,
causing B-thalassemia (23,24). Moreover, DMS interference experiments
(fig.3b, c) show that all the guanines (in the norn coding strand)
corresponding to the CACCC box are important for protein binding. This is in
agreement with the observation that all of the point mutations generated in
this element in the mouse 3-globin promoter have a strong effect on
transcription (22); in addition, B-thalassemic mutations may also involve
position -88 (25). Interestingly, neither footprinting nor DMS-interference
experiments, show significant involvement of the upstream CACCC box in
binding; this result indicates that nucleotide differences between the
sequences flanking the two CACCC boxes may also significantly affect the
ability of this element to bind nuclear proteins. The fact that mutations in
the proximal CACCC box have a drastic effect on I-globin transcription in
spite of the existence, few nucleotides upstream, of a similar element,
potentially able to compensate for the defective one, may well be explained
by our data indicating that the upstream CACCC box is unable to bind
significantly to factors B1-B4. This observation is in keeping with the
notion that the CACCC box is duplicated in human, rabbit and goat f-globin
genes, but not in mouse and other species.
Although we can demonstrate only little difference in the binding patterns of
factors B1-B3 and B4 (fig. 3 and data not shown), we believe B4 to be a
genuinely different protein than B1-B3. In fact, B4 is present only in
differentiated erythroid cells (induced K562 cells, fetal and adult
erythroblasts). In addition, mixing experiments between extracts generating
and non-generating band B4 indicate that the latters do not contain protease
or other activities capable of preventing the appearance of band 4. On the
other hand, protease treatment (fig.7) or preincubation of extracts under
different 6onditions fail to generate band B4 (in extracts not exhibiting
that band) or to increase its proportion relative to B1-B3 (in extracts
already showing band B4); these data indicate that B4 is unlikely to
represent a degradation product of B1-B3. Finally, B4 differs from B1-B3 as
to the specificity of binding to different promoters; we have previously
shown (ref. 34, fig.4) that a y-globin fragment containing the CACCC box
generates only three bands, conmparable to B1-B3 (and due to interaction with
the CACCC box, not shown) with all tested extracts, including induced K562
cells; no erythroid-specific band like B4 is seen with this fragment. This
observation is confirmed by experiments (fig.2) showing that the same
'y-globin fragment competes efficiently with the B-globin fragment for
generating bands B1-B3, but not for generating band B4. The erythroid
specificity of the protein generating band 4, its apparent developmental
regulation (as indicated by its absence in uninduced K562 cells and presence
in fetal and adult erythroblasts), its preference for the B-globin versus the
'y-globin promoter, and its ability to recognize a motif of proven functional
significance, suggest that the erythroid-specific nuclear factor generating
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band 4 might be involved in the erythroid-specific regulation of the 8-globin
promoter; this protein might be either a modified form of the ubiquitous
protein(s) generating bands 1-3, or an altogether different factor. it is
interesting in this context to recall a similar situation occurring in
B-lymphocites; these cells appear to contain both a ubiquitous and a
lymphocite-specific nuclear protein (28,30,32,35) capable of binding a
conserved "octamer" sequence, present in immunoglobulin as well as in several
non immunoglobulin genes. As the "octamer" alone is able to confer
lymphocite-specific expression to non immunoglobulin genes, like globin (36)
or renin (37), the lymphocite-specific factor may be involved in tissue
specific regulation of immunoglobulin genes; a similar model may be proposed
and is experimentally testable for B3-globin promoter regulation by the CACCC
binding factor. An objection to the role of the erythroid specific factor in
B-globin regulation might be suggested by the fac, that the endogenous
B-globin promoter is inactive in induced K562 cells (4), where the factor is
present. These data indicate that the factor may not be sufficient, per se,
but they do not rule out the possibility that the factor, in conjunction with
other proteins, is involved in, or necessary for, 13-globin gene expression.
K562 cells are "frozen" at a stage preceding, but close to, tnie fetal stage
when B3-globin synthesis initiates, as indicated by the observation of
6-globin gene transcription in these cells (38), and by a report suggesting
that 5'-azacytidine treatment may induce low level 8-globin transcription
(39). Other events, like B-globin gene demethylation (40) and 3' enhancer
activation (19) might additionally be required, at more advanced stages, to
promote 13-globin gene activity. Moreover, and more importantly, recent
experiments (41; Antoniou and Grosveld, quoted in ref. 42) indicate that the
lack of activity of the 13-globin promoter in K562 cells may be explained, at
least in part, by negative regulation acting on specific sequences of the
B-globin promoter; in addition, induction of K562 cells by hemin is reported
to allow expression of a transfected B3-globin promoter (41). These results
are fully in keeping with our observation that hemin induces the protein
generating band 4 in K562 cells (present paper), and causes the disappearance
of two proteins, binding to the B-globin promoter -253 to -230 and -207 to
-128 regions (in preparation). These same two proteins are absent in fetal
and adult erythroblasts.
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